
Cardiovascular Systems CSII
Quarterly report 2022-Q4
added 02-09-2023
Cardiovascular Systems Total Assets 2011-2026 | CSII
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Cardiovascular Systems
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 323 M | 353 M | 340 M | 219 M | 203 M | 194 M | 142 M | 171 M | 182 M | 96.9 M | 63.1 M | 46.8 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 353 M | 46.8 M | 194 M |
Quarterly Total Assets Cardiovascular Systems
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 312 M | 312 M | 323 M | 324 M | 326 M | 332 M | 353 M | 353 M | 349 M | 342 M | 340 M | 220 M | 224 M | 217 M | 219 M | 219 M | 207 M | 200 M | 203 M | 203 M | 190 M | 190 M | 194 M | 194 M | 159 M | 138 M | 142 M | 142 M | 151 M | 162 M | 171 M | 171 M | 181 M | 182 M | 182 M | 182 M | 181 M | 95.1 M | 96.9 M | 96.9 M | 56.6 M | 60.1 M | 63.1 M | 63.1 M | 52 M | 48.3 M | 46.8 M | 46.8 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 353 M | 46.8 M | 192 M |
Total Assets of other stocks in the Medical devices industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
GenMark Diagnostics, Inc.
GNMK
|
224 M | - | - | $ 1.77 B | ||
|
Axonics Modulation Technologies
AXNX
|
659 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
62.4 M | - | 1.37 % | $ 20.5 M | ||
|
Acutus Medical
AFIB
|
54 M | - | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
10.6 M | - | -5.86 % | $ 30.6 M | ||
|
BioSig Technologies
BSGM
|
842 K | - | 37.08 % | $ 85.7 M | ||
|
Conformis
CFMS
|
94 M | - | - | $ 16.4 M | ||
|
IRIDEX Corporation
IRIX
|
34.4 M | $ 1.35 | - | $ 21.8 M | ||
|
Apollo Endosurgery
APEN
|
110 M | - | - | $ 475 M | ||
|
Orthofix Medical
OFIX
|
851 M | $ 11.72 | -1.26 % | $ 464 M | ||
|
LENSAR
LNSR
|
66.3 M | $ 5.56 | -8.4 % | $ 64 M | ||
|
Avinger
AVGR
|
13.8 M | - | -20.74 % | $ 369 K | ||
|
CryoLife, Inc.
CRY
|
789 M | - | -4.14 % | $ 702 M | ||
|
AxoGen
AXGN
|
222 M | $ 32.61 | 2.71 % | $ 1.5 B | ||
|
CONMED Corporation
CNMD
|
2.33 B | $ 36.56 | -0.19 % | $ 1.13 B | ||
|
Penumbra
PEN
|
1.83 B | $ 334.17 | -0.41 % | $ 13 B | ||
|
Soliton, Inc.
SOLY
|
33.8 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
10.5 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
64.1 M | - | 0.03 % | $ 1.58 B | ||
|
Electromed
ELMD
|
53.8 M | $ 24.7 | 0.86 % | $ 209 M | ||
|
Misonix, Inc.
MSON
|
204 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
66.2 M | - | - | $ 111 M | ||
|
Insulet Corporation
PODD
|
3.19 B | $ 225.5 | -0.7 % | $ 15.9 B | ||
|
Intersect ENT, Inc.
XENT
|
227 M | - | - | $ 955 M | ||
|
Cytosorbents Corporation
CTSO
|
47.4 M | $ 0.7 | 3.3 % | $ 38.1 M | ||
|
Aethlon Medical
AEMD
|
7.36 M | $ 2.16 | -6.09 % | $ 3.37 M | ||
|
Profound Medical Corp.
PROF
|
43.9 M | $ 5.15 | -4.63 % | $ 180 M | ||
|
BIOLASE
BIOL
|
35.1 M | - | -13.19 % | $ 166 K | ||
|
Quanterix Corporation
QTRX
|
419 M | $ 3.82 | -3.05 % | $ 163 M | ||
|
AdaptHealth Corp.
AHCO
|
4.32 B | $ 11.48 | 10.7 % | $ 1.55 B | ||
|
Myomo
MYO
|
38.6 M | $ 0.7 | -1.83 % | $ 29.3 M | ||
|
Nano-X Imaging Ltd.
NNOX
|
210 M | $ 2.4 | -1.64 % | $ 141 M | ||
|
Invacare Corporation
IVC
|
771 M | - | - | $ 24.7 M | ||
|
EDAP TMS S.A.
EDAP
|
86.1 M | $ 3.91 | 4.83 % | $ 146 M | ||
|
OrthoPediatrics Corp.
KIDS
|
509 M | $ 15.91 | -3.4 % | $ 373 M | ||
|
Outset Medical
OM
|
264 M | $ 3.53 | -2.35 % | $ 53.7 K | ||
|
Inspire Medical Systems
INSP
|
907 M | $ 52.07 | -0.17 % | $ 1.53 B | ||
|
Sintx Technologies
SINT
|
9.51 M | $ 2.57 | 0.78 % | $ 7.13 M | ||
|
Pulmonx Corporation
LUNG
|
129 M | $ 1.31 | -5.76 % | $ 53.3 M | ||
|
Cutera
CUTR
|
346 M | - | -10.19 % | $ 1.99 M | ||
|
Dynatronics Corporation
DYNT
|
15.4 M | - | 14.99 % | $ 929 K | ||
|
Sensus Healthcare
SRTS
|
53 M | $ 3.96 | -3.65 % | $ 64.7 M | ||
|
InspireMD
NSPR
|
69.4 M | $ 1.79 | 3.47 % | $ 115 M | ||
|
Eargo
EAR
|
132 M | - | - | $ 10.2 M | ||
|
NuVasive
NUVA
|
2.22 B | - | - | $ 2.07 B | ||
|
Second Sight Medical Products
EYES
|
41.6 M | - | -0.97 % | $ 54.4 M |